Evaluation of immunogenicity of the 2008-2009 seasonal influenza vaccines by microneutralization test

Korean Journal of Pediatrics

Volumn 55, Issue 12, 2012, Pages 474-480

  Kim, Seung Youn ^a   Kim, Yun Kyung ^b   Eun, Byung Wook ^c   Kim, Nam Hee ^d   Kang, Eun Kyeong ^e   Lee, Byong Sop ^f   Lim, Jung Sub ^a   Lee, Jun Ah ^a   Kim, Dong Ho ^a  

^a Cancer Center Hospital   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Gachon University   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Dongguk University Ilsan Hospital   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

Author keywords

Child; Hemagglutination inhibition test; Influenza vaccines; Neutralization tests

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

ADOLESCENT; ADULT; ANIMAL CELL; ARTICLE; CHILD; CLINICAL ARTICLE; CYTOPATHOGENIC EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFANT; MALE; MICRONEUTRALIZATION TEST; NEWBORN; NONHUMAN; PRESCHOOL CHILD; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; VIRUS TITRATION;

EID: 84872238345     PISSN: 17381061     EISSN: 20927258     Source Type: Journal    
DOI: 10.3345/kjp.2012.55.12.474     Document Type: Article

References (22)

1. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000;342:225-31.
2. Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342:232-9.
3. Neuzil KM, Zhu Y, Griffin MR, Edwards KM, Thompson JM, Tollefson SJ, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002;185:147-52.
4. Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpaa R, Vuorinen T, et al. Burden of influenza in children in the community. J Infect Dis 2004;190:1369-73.
5. European Medicines Agency. Committee for proprietary medicinal products (CPMP). CPMP/BWP/214/96. Note for guidance on harmonization of requirements for influenza vaccines. London: European Medicines Agency; c1995-c2012 [cited 2004 Dec 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin e/2009/09/WC500003945.pdf.
6. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979;35:69-75.
7. Kayhty H. Immunogenicity assays and surrogate markers to predict vaccine efficacy. Dev Biol Stand 1998;95:175-80.
8. Arizona Department of Health Services, Division of Public Health Services, Bureau of State Laboratory Services. Modern methods for influenza detection and subtyping [Internet]. Phoenix: Arizona Department of Health Services; c2009-c2012 [cited 2012 Nov 22]. Available from: http://www.azdhs.gov/lab.
9. Okuno Y, Tanaka K, Baba K, Maeda A, Kunita N, Ueda S. Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. J Clin Microbiol 1990;28:1308-13.
10. Monto AS. Vaccines and antiviral drugs in pandemic preparedness. Emerg Infect Dis 2006;12:55-60.
11. Davenport FM, Hennessy AV, Francis T Jr. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med 1953;98:641-56.
12. World Health Organization, Department of Communicable Disease Surveillance and Response. WHO manual on animal influenza diagnosis and surveillance. 2002.5. Rev. 1 [Internet]. Geneva: World Health Organization; c2012 [cited 2012 Apr 12]. Available from: http://http://www.who.int/csr/resources/publications/influenza/en/whocds csrncs20025rev.pdf.
13. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972;70:767-77.
14. Benne CA, Harmsen M, De Jong JC, Kraaijeveld CA. Neutralization enzyme immunoassay for influenza virus. J Clin Microbiol 1994;32:987-90.
15. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37:937-43.
16. Tobita K, Sugiura A, Enomote C, Furuyama M. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med Microbiol Immunol 1975;162:9-14.
17. Centers for Disease Control and Prevention (CDC). Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009;58:521-4.
18. Gruber WC, Taber LH, Glezen WP, Clover RD, Abell TD, Demmler RW, et al. Live attenuated and inactivated influenza vaccine in school-age children. Am J Dis Child 1990;144:595-600.
19. Beyer WE, Palache AM, Osterhaus AD. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clin Drug Investig 1998;15:1-12.
20. Murphy BR, Nelson DL, Wright PF, Tierney EL, Phelan MA, Chanock RM. Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun 1982;36:1102-8.
21. Murphy BR, Kasel JA, Chanock RM. Association of serum antineuramini dase antibody with resistance to influenza in man. N Engl J Med 1972;286:1329-32.
22. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol 1983;37:529-49.